As new antimalarial drugs should achieve at least 95% efficacy and should no longer be recommended when cure rates fall below 90%, obtaining precision around such high proportions of efficacy requires very large sample sizes (59).
Noninferiority trials compare an investigational therapy with an established one and seek to determine that the former preserves a prespecified proportion of the efficacy of the latter.
Therefore if the vaccine has a protective effect in seronegative subjects, the study represents a worst case scenario to assess the proportion of vaccine efficacy correlated with seropositivity rate.
The primary efficacy endpoint was proportion of patients with efficacy failures (death, graft failure, locally read biopsy-proven acute rejection [BPAR], or loss to follow-up) within 12 months.
The primary efficacy endpoint was proportion of patients with efficacy failures (death, graft failure, locally read BPAR (Banff grade ≥1A), or lost to follow-up) within 12 months in the mITT population (i.e. all patients who received ≥1 dose of study drug).
This proportion of loss in efficacy is customarily accepted in controlled randomised clinical trials.
The importance of glutamine in ALL is highlighted by the fact that a significant proportion of the clinical efficacy of L-asparaginase, a cornerstone of therapy for this disease, is actually due to the glutaminase activity contained within such preparations (Reinert et al, 2006).
Difficulties in making benefit-risk judgments are further amplified by the fact that marketing may seek to create demand for drugs that is out of proportion to their efficacy.
Because the current state of phishing is juvenile and, inevitably, the sophistication of attacks will increase in direct proportion to the efficacy of any training program.
One of the two primary efficacy variables, proportion of responders (response), and one secondary efficacy variable, proportion of patients relapsing, were treated as categorical variables.
When the efficacy (proportion of treated children with HIV-RNA <400 copies/ml at 24 weeks) of one first-line regimen is greater than the efficacy of the other, GDP-based interpretation of cost-effectiveness generally supports the choice of the more effective first-line regimen (panel A).
